Citations

Showing 10 of 108152 citations.

Immunohistochemical Demonstration of Ghrelin in the Nontumorous Human Hypophysis
Rotondo, Angelo, Rotondo, Fabio , Scheithauer, Bernd W., Sharma, Soniya , Kovács, Kálmán, Syro, Luis V. , Cusimano, Michael D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.1002.5 Get It

Ghrelin, a 28 amino acid‐containing orexigenic peptide, is an endogenous ligand of the GH secretagogue receptor. It was extracted from the rat stomach, but is present in other organs. The aim of this work was to localize ghrelin by immunohistochemistry in autopsy‐derived non‐tumorous human pituitaries. Immunohistochemistry was performed using the streptavidin‐biotin‐peroxidase complex method and the results were analyzed independently by 3 of the authors. Double Immunostaining was also undertaken to determine which cell type was expressing both the adenohypophysial hormone and ghrelin. Results showed that ghrelin can be localized in the adenohypophysis. It's immunoexpression being cytoplasmic, weak to moderate, and present in only a subset of cells. The neurohypophysis is immunonegative. Double immunostaining showed that ghrelin is co‐localized with GH, ACTH and LH and is present to 51–90% of such cells. PRL, TSH and FSH cells are consistently non‐reactive. The role of ghrelin in adenohypophysial endocrine activity is not clear. It may well be that ghrelin exerts an autocrine‐paracrine effect and can modulate hormone synthesis and release.
Ghrelin Immunexpression in Pituitary Adenomas
Rotondo, Fabio , Scheithauer, Bernd W., Rotondo, Angelo, Latta, Eleanor, Kovács, Kálmán, Cusimano, Michael D. , Syro, Luis V.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.1001.13 Get It

Ghrelin, an orexigenic hormone occurs mainly in stomach, and in several tumor types. We investigated ghrelin immunopositivity using the streptavidin‐biotin‐peroxidase complex method in the full spectrum of pituitary adenoma subtypes. Quantification was undertaken by analyzing both the percentage of tumor cells stained for ghrelin and the staining intensity. Cytoplasmic ghrelin immunopositivity was identified in several adenoma subtypes. Not every cell was immunopositive; the intensity of staining differed among cells within the given lesion and among the various tumors. The highest scores were noted in GH adenomas exposed to somatostatin analogues. In decreasing order, lower scores were encountered in ACTH‐producing, silent subtype 1 and 2 adenomas in Cushing disease, silent subtype 3 adenomas, untreated GH adenomas, dopamine agonist‐treated PRL adenomas, gonadotroph adenomas, and ACTH adenomas in Nelson syndrome. No immunoreactivity was found in TSH, untreated PRL‐producing, and null cell adenomas. The high immunoexpression of ghrelin in GH adenomas exposed to somatostatin analogues, may be due to increased ghrelin synthesis or to suppression of its release.
IL‐10 suppresses pro‐fibrotic and matrix remodeling genes in normal and myxomatous mitral valves
Hagler, Michael A , Roos, Carolyn M, Hadley, Thomas A, Suri, Rakesh M. , Schaff, Hartzell V. , Miller, Jordan D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.1000.1 Get It

Myxomatous mitral valve disease (MMVD) is associated with increases in valvular fibrosis, matrix remodeling, and transforming growth factor beta (TGF β) signaling. While interleukin 10 (IL‐10) can suppress tissue fibrosis and matrix metalloproteinase (MMP) expression, its role in MMVD is unknown. We tested the hypotheses that reduced IL‐10 expression contributes to increased tissue fibrosis in MMVD, and that IL‐10 tonically suppresses TGF‐β signaling in normal mitral valves. We used qRT‐PCR to measure expression of IL10, TGF‐β1, MMP 2 and 9, and connective tissue growth factor (CTGF) in normal and myxomatous human mitral valves and in mitral and tricuspid valves from wild‐type and IL‐10 knockout mice. IL‐10 expression was significantly reduced in human myxomatous valves compared to normal valves (53± 12%), and was associated with increases in TGFβ, CTGF, and MMP2. Mitral valve gene expression patterns in IL‐10 −/− mice favored fibrosis and matrix remodeling compared to wild‐type littermates, with increases in TGF β (132±7%), CTGF (154±3%), and MMP9 (259±7%) (p< 0.05 for all), but not MMP2. Interestingly, expression of these genes was not altered in tricuspid valves from IL‐10 −/− mice. Collectively, these data are the first to show that IL‐10 tonically suppresses TGF β signaling in normal mitral valves and that deficiency of IL‐10 is likely to contribute to fibrosis and matrix remodeling in MMVD. NHLBI
Novel Mechanisms Contributing to Fibrosis and Matrix Remodeling in Myxomatous Mitral Valve Disease
Hadley, Thomas M., Hagler, Michael A , Suri, Rakesh M. , Schaff, Hartzell V. , Miller, Jordan D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.lb484 Get It

Myxomatous mitral valve disease is characterized by fibrosis and matrix degradation and increases in transforming growth factor beta‐1 (TGFbeta‐1). Little is known, however, about changes in molecules that regulate TGFbeta‐1 signaling in myxomatous valves. Thus, we tested the hypothesis that TGFbeta‐1 promotes valvular fibrosis and matrix remodeling in myxomatous valves through canonical Smad2 signaling and permissive reductions in Smad inhibitors. Expression of TGFbeta‐1, TGFbeta‐1 target genes (connective tissue growth factor, matrix metalloproteinases 2/9), E3 ubiquitin‐protein ligases (Smurf 1/2, which degrade Smad2), and NAD(P)H oxidase catalytic subunits (Nox 2, 4, and 5) was measured using quantitative real‐time RT‐PCR. Phospho‐Smad2 levels were measured using western blotting. TGFbeta‐1 expression was higher in myxomatous valves (138.3 ± 12.5% of control, n = 24 per group; p < 0.05), while CTGF and MMP2 were increased by 5‐ and 2‐fold, respectively. Surprisingly, phospho‐Smad2 levels were unchanged between myxomatous and control tissue due to selective increases in Smurf2 expression in myxomatous valve tissue (165.2 ± 17.7% of control, p < 0.05), as Smurf1 expression was unchanged. Expression of Nox2 and Nox4—which can drive pro‐fibrotic and matrix remodeling gene expression in other tissues—were significantly elevated in myxomatous valves (211 ± 44% and 224 ± 35 % of control, respectively; p < 0.05). In conclusion, our data suggest that canonical TGFbeta‐1/Smad2 signaling is not required for progression of myxomatous valve disease, and that reducing Nox2‐and Nox4‐derived reactive oxygen species may be a novel intervention to slow progression of fibrosis and matrix remodeling in myxomatous valves.
Participant compliance and vital sign changes associated with a low, normal, and high dietary sodium protocol
Knutson, Jean N., Winslow, Nolan , White, Alexander I, Eisenach, John H., Silva, Bruno M.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.lb286 Get It

Salt sensitivity is a major cardiovascular focus, but extremes of sodium (Na + ) intake can affect subject dropout rates. We analyzed dietary compliance and baseline cardiovascular indices in an ongoing genotype‐phenotype protocol in healthy young adults. Study visits followed 5 day consumption of 3 daily Na + levels: normal (150) low (10) and high (400 mmol/day). Compliance was determined by 24‐hour Na + excretion. Vital signs were obtained on each visit. Of the first 30 subjects to date, one was unable to tolerate the low Na + diet due to palatability. Mean ± SE urine Na + excretion was 113 ± 27, 25 ± 18 and 328 ±110 mmol for normal, low, and high Na + , respectively. Low Na + caused a significant weight change of −1.6 ± 2.2 kg from screen. High Na + diet decreased resting HR (−2.7 bpm) and increased 24hr urine volume 25% from the normal Na + diet. No correlation was found between urine indices and weight change in the subjects. This dietary sodium crossover study is generally well‐tolerated with high compliance. Low Na + diet appears to cause weight loss; high Na + causes an increase in urine volume and decrease in HR, but no effects on weight or blood pressure. HL 089331
Ano1 as a regulator of proliferation
Stanich, Jennifer E., Eisenman, Seth T., Bardsley, Michael R., Rock, Jason R. , Ördög, Tamás , Farrugia, Gianrico , Gibbons, Simon J. , Harfe, Brian D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.lb115 Get It

Ano1 is a Ca 2+ activated Cl − channel expressed in several proliferating cell types including various epithelia, gastrointestinal stromal tumors, interstitial cells of Cajal (ICC) and CFPAC‐1 cells. The aim of this study was to determine if Ano1 regulates proliferation. ICC from Ano1 (−/−) and Ano1 (+/+) mice were cultured with Cl − channel inhibitors or in low Cl − media. CFPAC‐1 cells grown in low Cl − media were pulsed with EdU for 1 h. Incorporation was measured by flow cytometry. For immunoblots on mouse jejunum, antibodies to pRb, phospho(Ser773)‐pRb and GAPDH were used. Fewer proliferating ICC were detected in Ano1 (−/−) cultures (15 ± 3.5% Ki67 + ICC vs 25 ± 4% in Ano1 (+/+) , mean ± SEM, n = 4, p < 0.05). Cl − channel inhibitors DIDS (10 μM), niflumate (10 μM) and tamoxifen (1 μM) decreased ICC proliferation by 53, 53 and 59%, respectively ( p < 0.05). This effect was reduced in cultures from Ano1 (−/−) mice (29% and 19 % decrease, 22% increase, p > 0.05). Fewer proliferating ICC and CFPAC‐1 cells were detected in low Cl − media (% EdU + ICC: 120 mM; 19.8 ± 5.3, 12 mM; 8.5 ± 3.2, n = 4, and % EdU + CFPAC‐1: 120 mM; 29.5, 12 mM; 14.3 p < 0.05). Proportionally less Ser773‐phosphorylated pRb was detected in jejunum from Ano1 (−/−) mice (Ano1 (+/+) ; 5.98 ± 0.78, Ano1 (−/−) ; 3.60 ± 0.49, mean ± SEM, n = 7, p < 0.05). In conclusion, Ano1 regulates proliferation possibly by promoting the G 1 /S transition of the cell cycle. Support: DK57061 and DK68055.
Regulation of Cellular Transformation Genes by the Circadian Clock Protein Per1 in the Kidney
Cheng, Kit‐Yan, Copland, John A. , Gilkes, Janine, Gumz, Michelle L. , Roemeling, Christina A. Von

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.lb113 Get It

The importance of normal circadian rhythms is underscored by the known relationship between circadian disruption and increased cancer risk. The goal of the present study was to investigate the role of the circadian clock in the regulation of genes encoding products that function in cellular transformation. Microarray analysis was used to evaluate changes in gene expression following siRNA‐mediated knockdown of the circadian clock protein Per 1 in a murine renal collecting duct cell line (mpkCCD c14 ). Several hundred genes underwent significant changes in expression following Per1 knockdown, including 21 genes involved in cellular transformation. Cdkn1a and Cyclin E1, both cell cycle regulators, claudin 1 and 12, involved in tight junction formation, and sFRP1, a regulator of Wnt signaling and a tumor suppressor in renal cell carcinoma, were all confirmed as novel Per1 target genes. In an independent sample set, Cdkn1a, Cyclin E1, Claudin 1 and 12, and sFRP1 were all up‐regulated following Per1 knockdown in mpkCCD c14 cells. The chromophobe subtype of renal cell carcinoma is thought to arise from the collecting duct. Interestingly, dysregulation of the circadian clock genes Per2 and Cry2 was observed in patient chromophobe tumor samples compared to normal tissues. These observations support a role for the circadian clock in the control of cellular transformation in the kidney.
Mechanisms of Neurotrophin Action on Human Airway Smooth Muscle
Abcejo, Amard J., Aravamudan, Bharathi, Sathish, Venkatachalem , Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.864.9 Get It

Neurotrophins (NTs), which play an integral role in directing proper neuronal development and function, have been found in non‐neuronal tissue (including lung), but their role is still under investigation. We previously found NTs such as brain‐derived neurotrophic factor (BDNF) and neurotrophin‐3 (NT3) and their receptors to be expressed in human airway smooth muscle (ASM). In this study, we hypothesized that NTs contribute to regulation of ASM function via regulation of mechanisms that control intracellular Ca 2+ ([Ca 2+ ] i ). Human ASM cells isolated from lung samples incidental to patient surgery were incubated for 24 or 48 h in medium (control), 10 nM BDNF or NT3 in the presence or absence of inhibitors of signaling pathways such as MAP kinases (PD98059), PI3/Akt (Wortmannin) and NFκB (SN50). In fluo‐4 loaded cells, [Ca 2+ ] i responses to ACh and histamine were significantly higher following BDNF and NT3 exposure: effects that were blunted by SN50 and PD98059, but not Wortmannin. Western analysis of cell lysates showed higher expressions of Ca 2+ regulatory proteins such as Orai1, TRPC3, and SERCA with 1 or 10nM BDNF exposure, but decreased expression by NT3. These data show that NTs activate signaling pathways in human ASM that lead to enhanced [Ca 2+ ] i responses, and could thus contribute to airway hyperresponsiveness. Supported by NIH grants HL088029, HL090595 and FAMRI.
Cigarette smoke enhances TRPC and CD38 expression in human airway smooth muscle
Kiel, Alexander , Thompson, Michael A, Wylam, Mark E. , Burkholder, David B. , Kiel, Alexander, Sathish, Venkatachalem , Vassallo, Robert , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.864.7 Get It

Smoking contributes to or exacerbates diseases such as asthma and COPD, where airway hyperreactivity is a key feature. Enhanced Ca 2+ in airway smooth muscle contributes to airway hyperreactivity. We previously determined that the cytokine TNFα upregulates expression of Ca 2+ regulatory molecules such as membrane bound bifunctional enzyme CD38 and Ca 2+ influx regulatory TRPC3 in human airway smooth muscle cells (HASM). We hypothesized that cigarette smoke (CS) is an inflammatory stimulus that upregulates Ca 2+ regulatory mechanisms in HASM. Western analysis showed increased expression of CD38, TRPC3 and TRPC6 in lungs from mice following 4 week in vivo CS exposure. These proteins were also upregulated in HASM cells incubated in 1 or 2% CS extract (CSE), as well as in HASM samples from patients with COPD (compared to controls). In fura‐2 loaded HASM cells, exposure to CSE enhanced histamine‐mediated Ca 2+ mobilization as well as store‐operated calcium entry: effects substantially blunted by TRPC3 siRNAs. Finally, in living lung slices of mice exposed for 4 weeks to CS, ACh‐induced airway contractility was substantially greater, compared to controls. These results indicate that CS upregulates expression and function of Ca 2+ regulatory proteins, thus contributing to airway hyperreactivity in smoking related diseases. Supported by the Annenberg Foundation (MEW), HL090595 (CMP), FAMRI (RV, YSP).
Hyperoxia enhances intracellular calcium in human fetal airway smooth muscle via cyclic nucleotide regulation of brain‐derived neurotrophic factor release
Thompson, Michael A, Martin, Richard J, Zaidi, Syed I. A. , Martin, Richard J, Pandya, Hitesh , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 25 | Issue: S1 | Pages: No page available

10.1096/fasebj.25.1_supplement.864.3 Get It

Supplemental oxygen places the immature airway at risk for bronchopulmonary dysplasia and asthma. Hyperoxia enhances intracellular Ca2+ ([Ca2+]i) and contractility of airway smooth muscle (ASM), and impairs relaxation (potentially by altering cyclic nucleotide levels). The neurotrophin brain‐derived neurotrophic factor (BDNF) enhances [Ca2+]i in adult ASM. We tested the hypothesis that hyperoxia‐induced airway hyperreactivity involves cyclic nucleotide‐mediated enhancement of BDNF release in human fetal (18–22 weeks) ASM cells exposed to 21% (normoxia) or 80% oxygen in the presence/absence of 1mM dibutyryl cAMP (DBcAMP) or 8‐Br‐cGMP. BDNF release (ELISA) was increased by hyperoxia (143% of normoxia). DBcAMP enhanced BDNF release with normoxia (242% of baseline) and even more with hyperoxia (280%), while 8‐Br‐cGMP blunted BDNF release in normoxia (57% of baseline) but to a lesser extent with hyperoxia (68% of baseline). Measurements of [Ca2+]i in fetal ASM cells showed DBcAMP increasing [Ca2+]i responses to histamine or ACh (effects enhanced with hyperoxia). Further, chelation of released BDNF using chimeric TrkB‐Fc (1?g/ml) reversed DBcAMP effects and blunted [Ca2+]i responses to below controls. We conclude that an imbalance between cAMP vs. cGMP enhances BDNF release in the developing airway, resulting in greater airway reactivity with hyperoxia. Supported by NIH grants HL056470 and HL088029